Ferroptosis Inducers
|
Erastin |
Inhibition of system Xc- and VDAC2/3 |
10
|
Sulphasalazine |
Inhibition of system Xc-
|
10, 48
|
Sorafenib |
Inhibition of system Xc- and Nrf2 |
49, 50
|
Glutamate |
Inhibition of system Xc- and Cys deprivation |
51
|
RSL3 |
GPX4 inactivation |
32
|
Solasonine |
GPX4 inactivation |
52
|
Altretamine |
GPX4 inactivation and promotion of ROS |
53
|
FINO2 |
GPX4 inactivation and oxidation of unstable iron |
54
|
FIN56 |
GPX4 inactivation and CoQ10 deletion |
55
|
BSO |
GSH deletion |
32
|
DPI2 |
GSH deletion |
32
|
Cisplatin |
GSH deletion and GPX4 inactivation |
56
|
Artesunate |
Degradation of ferritin and increased cellular iron |
57
|
iFSP |
Inhibition of FSP1 |
34
|
Brequinar |
Inhibition of DHODH |
36
|
Ferroptosis Inhibitors
|
Ferrostatin-1 |
Inhibition of lipid peroxidation |
58
|
Liproxstatin-1 |
Inhibition of lipid peroxidation |
33
|
Necrostatin-1 |
Inhibition of lipid peroxidation |
33, 59
|
SRS 16-86 |
Inhibition of lipid peroxidation |
60
|
SRS 11-92 |
Inhibition of lipid peroxidation |
58
|
Nuciferine |
Inhibition of lipid peroxidation |
61
|
TEMPO |
Elimination of ROS |
62
|
Phenothiazine |
Elimination of ROS |
63
|
Phenoxazine |
Elimination of ROS |
63
|
Diarylamine |
Elimination of ROS |
63
|
Vitamin E |
Elimination of ROS and inactivation of LOXs |
27, 64
|
NDGA |
Inactivation of LOXs |
65
|
Zileuoton |
Inactivation of LOXs |
66
|
Baicalein |
Inactivation of LOXs and ACSL4 |
65, 67
|
Thiazolidinedione |
Inactivation of ACSL4 |
68
|
Dexrazoxane |
Depletion of cellular iron |
69
|
Deferoxamine |
Depletion of cellular iron |
69
|
Deferiprone |
Depletion of cellular iron |
70
|
β-Mercaptoethanol |
Increased cysteine intake |
71
|
Vitamin K |
Activation of FSP1 |
72
|
Curcumin |
Activation of Nrf2 |
73
|
Quercetin |
Activation of Nrf2 and elimination of ROS |
74, 75
|
MCTR1 |
Activation of Nrf2 |
76
|
Irisin |
Activation of Nrf2 |
77
|